Guardant Health (GH) reported $281.27 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 39.4%. EPS of -$0.50 for the same period compares to -$0.62 a year ago.
The reported revenue represents a surprise of +0.47% over the Zacks Consensus Estimate of $279.96 million. With the consensus EPS estimate being -$0.42, the EPS surprise was -18.12%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Guardant Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total tests performed (oncology tests): 79,000 versus the three-analyst average estimate of 75,360.
- Revenue- Oncology: $189.95 million compared to the $186.77 million average estimate based on four analysts.
- Revenue- Licensing and other: $2.18 million versus $2 million estimated by four analysts on average.
- Revenue- Screening: $35.13 million versus the four-analyst average estimate of $27.31 million.
- Revenue- Biopharma and data: $54.01 million compared to the $50.47 million average estimate based on four analysts.
View all Key Company Metrics for Guardant Health here>>>
Shares of Guardant Health have returned -7.2% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Guardant Health, Inc. (GH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
